Pathogenesis of Liver-Dependent Acute Lung Injury

肝依赖性急性肺损伤的发病机制

基本信息

  • 批准号:
    7318495
  • 负责人:
  • 金额:
    $ 38.25万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-07-18 至 2012-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): There are connections between hepatic function and acute lung injury: a) ARDS in the setting of hepatic failure is almost uniformly fatal; b) hepatic dysfunction is common in patients with ARDS; and c) animal studies demonstrate release of pro-inflammatory cytokines from the liver in response to endotoxemia or hepatic ischemia. In an in situ perfused swine preparation we find that endotoxin induced lung injury only occurs when the liver is included in the circulation. We conclude that endotoxin does not injure the lung directly, but "primes" the lung for injury that is mediated by endotoxin induced release of mediators from the liver. We hypothesize that: a) Direct effects of endotoxin prime the lung for injury, but injury requires mediators released from the liver; b) Endotoxemia induces increased hepatic expression of gene(s) encoding protein(s) secreted into the circulation that mediate liver dependent lung injury, c) Bone marrow derived stem cells are critical modulators of the acute inflammatory response to endotoxemia in both the liver and the lungs and; d) Suppression of endotoxin induced acute inflammation and lung injury by bone marrow cells is primarily an effect of a subset of non-hematopoietic, mesenchymal-like stem cells. We will test these hypotheses by: 1) Determining whether endotoxin "priming" of the lung for injury is necessary for injury caused by endotoxin induced release of mediators from the liver, determining molecular responses to endotoxemia in both the lungs and liver and identifying endotoxin induced mediators produced in the liver and released into the circulation that mediate lung injury; 2) Determining effects of bone marrow derived cells on endotoxin induced inflammation (lung and liver) and release of mediators by the liver, characterizing effects of these cells on endotoxin induced molecular responses, determining whether bone marrow cells must be delivered to both the lungs and the liver to prevent lung injury, and determining whether the population of effective marrow derived cells is non-hematopoietic and mesenchymal-like; and 3) Determining in vivo the effects of access to an expanded pool of bone marrow cells on endotoxin-induced inflammation and lung injury and characterizing the populations of cells recruited to the lungs and the liver in vivo following endotoxemia in a parabiotic mouse preparation. These studies will elucidate mechanisms of acute lung inflammation and injury and identify novel potentials for therapy.
描述(由申请方提供):肝功能和急性肺损伤之间存在联系:a)在肝衰竭的情况下,ARDS几乎是一致致命的; B)在ARDS患者中肝功能障碍很常见; c)动物研究表明,促炎细胞因子在内毒素血症或肝缺血时从肝脏释放。在原位灌注的猪制备中,我们发现内毒素诱导的肺损伤仅在肝脏被包括在循环中时发生。我们的结论是,内毒素不直接损伤肺,但“启动”肺损伤,是由内毒素诱导的介质从肝脏释放介导的。我们假设:B)内毒素血症诱导编码分泌到循环中的蛋白质的基因的肝表达增加,所述蛋白质介导肝依赖性肺损伤,c)骨髓来源的干细胞是肝和肺中对内毒素血症的急性炎症反应的关键调节剂; d)骨髓细胞对内毒素诱导的急性炎症和肺损伤的抑制主要是非造血间充质样干细胞亚群的作用。1)确定肺损伤的内毒素“引发”是否是由内毒素诱导的介质从肝脏释放引起的损伤所必需的,确定肺和肝脏中对内毒素血症的分子反应,并鉴定在肝脏中产生并释放到介导肺损伤的循环中的内毒素诱导的介质; 2)确定骨髓来源的细胞对内毒素诱导的炎症的影响(肺和肝脏)和肝脏释放介质,表征这些细胞对内毒素诱导的分子反应的影响,确定是否必须将骨髓细胞输送到肺和肝脏以防止肺损伤,并确定有效的骨髓衍生细胞群是否是非造血的和间充质样的;和3)体内确定接近扩增的骨髓细胞库对内毒素诱导的炎症和肺损伤的影响,并表征在异种小鼠制备物中内毒素血症后体内募集到肺和肝的细胞群。这些研究将阐明急性肺部炎症和损伤的机制,并确定新的治疗潜力。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

KENNETH L BRIGHAM其他文献

KENNETH L BRIGHAM的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('KENNETH L BRIGHAM', 18)}}的其他基金

Pathogenesis of Liver-Dependent Acute Lung Injury
肝依赖性急性肺损伤的发病机制
  • 批准号:
    7624160
  • 财政年份:
    2007
  • 资助金额:
    $ 38.25万
  • 项目类别:
Pathogenesis of Liver-Dependent Acute Lung Injury
肝依赖性急性肺损伤的发病机制
  • 批准号:
    7805421
  • 财政年份:
    2007
  • 资助金额:
    $ 38.25万
  • 项目类别:
Pathogenesis of Liver-Dependent Acute Lung Injury
肝依赖性急性肺损伤的发病机制
  • 批准号:
    7470584
  • 财政年份:
    2007
  • 资助金额:
    $ 38.25万
  • 项目类别:
Liver Lung Interactions in Lung Inflammation
肺部炎症中肝肺的相互作用
  • 批准号:
    7000758
  • 财政年份:
    2004
  • 资助金额:
    $ 38.25万
  • 项目类别:
Role of Eicosanoids In Modulating Endotoxin Induced Live
类二十烷酸在调节内毒素诱导的活体中的作用
  • 批准号:
    6577680
  • 财政年份:
    2002
  • 资助金额:
    $ 38.25万
  • 项目类别:
Alpha-1 Antitrypsin Gene Therapy for Cystic Fibrosis
Alpha-1 抗胰蛋白酶基因治疗囊性纤维化
  • 批准号:
    6338316
  • 财政年份:
    2001
  • 资助金额:
    $ 38.25万
  • 项目类别:
In Vivo System - Screening Anti-Inflammatory Compounds
体内系统 - 筛选抗炎化合物
  • 批准号:
    6337850
  • 财政年份:
    2001
  • 资助金额:
    $ 38.25万
  • 项目类别:
p20, Molecular Shortstop for Inflammatory Lung Diseases
p20,炎症性肺病的分子游击剂
  • 批准号:
    6612817
  • 财政年份:
    2000
  • 资助金额:
    $ 38.25万
  • 项目类别:
p20, Molecular Shortstop for Inflammatory Lung Diseases
p20,炎症性肺病的分子游击剂
  • 批准号:
    6485715
  • 财政年份:
    2000
  • 资助金额:
    $ 38.25万
  • 项目类别:
P20, 'MOLECULAR SHORTSTOP' FOR INFLAMATORY LUNG DISEASES
P20,炎症性肺病的“分子捷径”
  • 批准号:
    6076035
  • 财政年份:
    2000
  • 资助金额:
    $ 38.25万
  • 项目类别:

相似海外基金

Combinatorial cytokine-coated macrophages for targeted immunomodulation in acute lung injury
组合细胞因子包被的巨噬细胞用于急性肺损伤的靶向免疫调节
  • 批准号:
    10648387
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Inducible HMGB1 antagonist for viral-induced acute lung injury.
诱导型 HMGB1 拮抗剂,用于治疗病毒引起的急性肺损伤。
  • 批准号:
    10591804
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
MAP2K1 AND MAP2K2 IN ACUTE LUNG INJURY AND RESOLUTION
MAP2K1 和 MAP2K2 在急性肺损伤中的作用及缓解
  • 批准号:
    10741574
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Lung epithelial cell-derived C3 in acute lung injury
肺上皮细胞衍生的 C3 在急性肺损伤中的作用
  • 批准号:
    10720687
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Examining the role of TRMT1 and tRNA methylation in acute lung injury and ARDS
检查 TRMT1 和 tRNA 甲基化在急性肺损伤和 ARDS 中的作用
  • 批准号:
    10719249
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Development of a new treatment for COVID-19-related acute lung injury targeting the microbiota-derived peptide corisin
针对微生物群衍生肽 corisin 开发治疗 COVID-19 相关急性肺损伤的新疗法
  • 批准号:
    23K07651
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Probing immunovascular mechanobiology in pneumonia-associated acute lung injury at the single capillary level
在单毛细血管水平探讨肺炎相关急性肺损伤的免疫血管力学生物学
  • 批准号:
    10679944
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
The amyloid precursor protein protects against acute lung injury
淀粉样前体蛋白可预防急性肺损伤
  • 批准号:
    10575258
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Role of macrophages and miRNA in regulating lung macrophage polarization and lung pathogenesis during respiratory virus-induced acute lung injury in normal and diabetic Syrian hamsters.
正常和糖尿病叙利亚仓鼠呼吸道病毒引起的急性肺损伤期间巨噬细胞和 miRNA 在调节肺巨噬细胞极化和肺部发病机制中的作用。
  • 批准号:
    10701207
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
Roles of N-glycans on neutrophil beta2 integrins in progression of acute lung injury
N-聚糖对中性粒细胞β2整合素在急性肺损伤进展中的作用
  • 批准号:
    10837431
  • 财政年份:
    2023
  • 资助金额:
    $ 38.25万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了